Literature DB >> 8040287

Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma.

S Zhan1, D N Shapiro, L J Helman.   

Abstract

The insulin-like growth factor II (IGF2) gene is exclusively silent at the maternal allele in the mouse as well as in normal human tissues and is expressed at a high level in rhabdomyosarcoma (RMS). We report here that the normally imprinted allele of the IGF2 gene is activated in RMS tumors as well as in one RMS cell line. Since overexpression of IGF2 has been shown to be important in the pathogenesis of RMS, our data suggest that loss of imprinting (LOI) may lead to overexpression of IGF2 and play an important role in the onset of RMS. Furthermore, embryonal RMS usually has loss of heterozygosity (LOH) with paternal disomy of the IGF2 locus. One informative embryonal RMS tumor evaluated in this study was heterozygous at the IGF2 allele and had LOI, raising the possibility that LOI may be the functional equivalent of LOH in this tumor with both events leading to overexpression of IGF2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8040287      PMCID: PMC296329          DOI: 10.1172/JCI117344

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Rhabdomyosarcoma: a clinicopathological study and classification of 39 cases.

Authors:  R C HORN; H T ENTERLINE
Journal:  Cancer       Date:  1958 Jan-Feb       Impact factor: 6.860

2.  Maternal allele loss in Wilms' tumour.

Authors:  J C Williams; K W Brown; M G Mott; N J Maitland
Journal:  Lancet       Date:  1989-02-04       Impact factor: 79.321

3.  Parental legacy determines methylation and expression of an autosomal transgene: a molecular mechanism for parental imprinting.

Authors:  J L Swain; T A Stewart; P Leder
Journal:  Cell       Date:  1987-08-28       Impact factor: 41.582

4.  Maternal inhibition of hepatitis B surface antigen gene expression in transgenic mice correlates with de novo methylation.

Authors:  M Hadchouel; H Farza; D Simon; P Tiollais; C Pourcel
Journal:  Nature       Date:  1987 Oct 1-7       Impact factor: 49.962

5.  Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping.

Authors:  H J Scrable; D P Witte; B C Lampkin; W K Cavenee
Journal:  Nature       Date:  1987 Oct 15-21       Impact factor: 49.962

6.  Degree of methylation of transgenes is dependent on gamete of origin.

Authors:  C Sapienza; A C Peterson; J Rossant; R Balling
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

7.  Cancer genetics. Genomic imprinting and embryonal tumours.

Authors:  W Reik; M A Surani
Journal:  Nature       Date:  1989-03-09       Impact factor: 49.962

8.  A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting.

Authors:  T M DeChiara; A Efstratiadis; E J Robertson
Journal:  Nature       Date:  1990-05-03       Impact factor: 49.962

9.  Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism.

Authors:  A Koufos; M F Hansen; N G Copeland; N A Jenkins; B C Lampkin; W K Cavenee
Journal:  Nature       Date:  1985 Jul 25-31       Impact factor: 49.962

10.  A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting.

Authors:  H Scrable; W Cavenee; F Ghavimi; M Lovell; K Morgan; C Sapienza
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more
  51 in total

Review 1.  Genomic imprinting: implications for human disease.

Authors:  J G Falls; D J Pulford; A A Wylie; R L Jirtle
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

2.  Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma.

Authors:  J Anderson; A Gordon; A McManus; J Shipley; K Pritchard-Jones
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

3.  Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.

Authors:  Doris Phelps; Kathryn Bondra; Star Seum; Christopher Chronowski; Justin Leasure; Raushan T Kurmasheva; Steven Middleton; Dian Wang; Xiaokui Mo; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2015-04-01       Impact factor: 3.167

Review 4.  Genomic imprinting and cancer.

Authors:  J A Joyce; P N Schofield
Journal:  Mol Pathol       Date:  1998-08

5.  Is p57KIP2 mutation a common mechanism for Beckwith-Wiedemann syndrome or somatic overgrowth?

Authors:  K Okamoto; I M Morison; A E Reeve; N Tommerup; H R Wiedemann; U Friedrich
Journal:  J Med Genet       Date:  1998-01       Impact factor: 6.318

6.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

Review 7.  The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors.

Authors:  Martin G Belinsky; Lori Rink; Kathy Q Cai; Michael F Ochs; Burton Eisenberg; Min Huang; Margaret von Mehren; Andrew K Godwin
Journal:  Cell Cycle       Date:  2008-10-07       Impact factor: 4.534

8.  Evidence that Igf2 down-regulation in postnatal tissues and up-regulation in malignancies is driven by transcription factor E2f3.

Authors:  Julian C Lui; Jeffrey Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

9.  Monoallelic expression of the insulin-like growth factor-2 gene in ovarian cancer.

Authors:  K Yun; M Fukumoto; Y Jinno
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

10.  The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs).

Authors:  Maria A Pantaleo; Annalisa Astolfi; Margherita Nannini; Guido Biasco
Journal:  J Transl Med       Date:  2010-11-15       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.